The safety profile of belrestotug + dostarlimab was broadly consistent with known checkpoint inhibitor combinations. However, there was an increase in immune-related adverse events compared to dostarlimab monotherapy, with the most frequent treatment-related adverse events being skin and subcutaneous tissue disorders (50%) and endocrine disorders (26%).